The US FDA has granted AstraZeneca's (AZ) Brilinta a priority review for patients with a history of heart attack. The announcement is good news for AZ, which has identified Brilinta (ticagrelor ...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).

that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the US and Brilique in Europe), manufactured by AstraZeneca. Peter Doshi, senior editor at The BMJ ...

Doctors have raised serious concerns about the efficacy of AstraZeneca's Brilinta, which is given to people with a history of heart attack or blood vessel conditions that put them at risk of ...

P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...